08:20 AM EDT, 05/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We reduce our target price to $53 from $61, reflecting a 24.3x multiple our FY 26 (Jun.) EPS estimate, below TECH's 10-year historical forward P/E average. We lower our FY 25 EPS estimate to $1.82 from $1.91 and keep our FY 26 EPS estimate at $2.18. Despite a rather solid Q3 FY 25, we expect to see a slowdown in TECH's sales in Q4 of FY 25 amid ongoing uncertainties related to NIH funding and increasing U.S. academic clients spending caution. We think sales will grow by 5.2% Y/Y vs. 6.2% Y/Y earlier in FY 25, after rising by a modest 2% Y/Y in FY 24. The Diagnostics and Spatial Biology segment has been the fastest growing business in FY 24 on strong demand for spatial and molecular diagnostics. Yet, due to its higher exposure to U.S. academia versus other segments, we expect its growth to continue to slow down. The segment's Q3 sales were $89M, up 2% Y/Y, yet slower than previous quarters, despite strong performance in the COMET platform and continued solid growth in the ExoDx prostate cancer test.